Agilent highlighted how lab automation can scale characterization workflows for antibody-drug conjugates (ADCs) and other targeted biologics, focusing on faster, more reproducible development. Shweta Shukradas discussed instrumentation and automation strategies designed to reduce variability and improve repeatability in early discovery through preclinical stages. As targeted biologics evolve toward more complex constructs and higher-throughput screening, characterization bottlenecks can slow iteration cycles. The emphasis in the report is on enabling quicker determination of critical attributes while maintaining consistent data quality. For biotech teams running ADC programs, improved automation and standardized instrumentation reduce rework and can shorten the time between analytical findings and engineering decisions. The update also underscores that many “platform” advantages in therapeutic development are increasingly tied to how well labs can operationalize repeatable measurement across programs.